search
Back to results

A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)

Primary Purpose

Diabetes Mellitus, Non-Insulin-Dependent

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
sitagliptin phosphate
Comparator: voglibose
Sponsored by
Merck Sharp & Dohme LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Non-Insulin-Dependent

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients have type 2 diabetes mellitus on diet/exercise therapy

Exclusion Criteria:

  • Patients have type 1 diabetes mellitus

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Sitagliptin 50 mg QD

    Voglibose 0.2 mg TID

    Arm Description

    sitagliptin 50 mg orally once daily (QD=once daily)

    voglibose 0.2 mg orally three times daily (TID= three times daily)

    Outcomes

    Primary Outcome Measures

    Change From Baseline in HbA1c at Week 12
    HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent.

    Secondary Outcome Measures

    Change From Baseline in Fasting Plasma Glucose at Week 12
    Change from baseline at Week 12 is defined as fasting plasma glucose at Week 12 minus fasting plasma glucose at Week 0.
    Change From Baseline in 2 Hour Postprandial Glucose at Week 12
    Change from baseline at Week 12 is defined as 2-hour postprandial glucose Week 12 minus 2-hour postprandial glucose Week 0.

    Full Information

    First Posted
    December 13, 2006
    Last Updated
    February 3, 2016
    Sponsor
    Merck Sharp & Dohme LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00411554
    Brief Title
    A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
    Official Title
    Sitagliptin (MK0431) Phase III Double-blind Comparative Study - Type 2 Diabetes Mellitus -
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2007 (undefined)
    Primary Completion Date
    August 2007 (Actual)
    Study Completion Date
    August 2007 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Merck Sharp & Dohme LLC

    4. Oversight

    5. Study Description

    Brief Summary
    The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetes Mellitus, Non-Insulin-Dependent

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    319 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Sitagliptin 50 mg QD
    Arm Type
    Experimental
    Arm Description
    sitagliptin 50 mg orally once daily (QD=once daily)
    Arm Title
    Voglibose 0.2 mg TID
    Arm Type
    Active Comparator
    Arm Description
    voglibose 0.2 mg orally three times daily (TID= three times daily)
    Intervention Type
    Drug
    Intervention Name(s)
    sitagliptin phosphate
    Other Intervention Name(s)
    MK0431
    Intervention Description
    sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks
    Intervention Type
    Drug
    Intervention Name(s)
    Comparator: voglibose
    Other Intervention Name(s)
    voglibose
    Intervention Description
    voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks
    Primary Outcome Measure Information:
    Title
    Change From Baseline in HbA1c at Week 12
    Description
    HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent.
    Time Frame
    Baseline and Week 12
    Secondary Outcome Measure Information:
    Title
    Change From Baseline in Fasting Plasma Glucose at Week 12
    Description
    Change from baseline at Week 12 is defined as fasting plasma glucose at Week 12 minus fasting plasma glucose at Week 0.
    Time Frame
    Baseline and Week 12
    Title
    Change From Baseline in 2 Hour Postprandial Glucose at Week 12
    Description
    Change from baseline at Week 12 is defined as 2-hour postprandial glucose Week 12 minus 2-hour postprandial glucose Week 0.
    Time Frame
    Baseline and Week 12

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    20 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients have type 2 diabetes mellitus on diet/exercise therapy Exclusion Criteria: Patients have type 1 diabetes mellitus
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Monitor
    Organizational Affiliation
    Merck Sharp & Dohme LLC
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    20590736
    Citation
    Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, Nishii M, Arjona Ferreira JC, Amatruda JM. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab. 2010 Jul;12(7):613-22. doi: 10.1111/j.1463-1326.2010.01197.x.
    Results Reference
    result

    Learn more about this trial

    A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)

    We'll reach out to this number within 24 hrs